Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B‑cell malignancies (Review)

Xia,Bing; Qu,Fulian; Yuan,Tian; Zhang,Yizhuo

doi:10.3892/ol.2015.3802

Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B‑cell malignancies (Review)

Authors:
- Bing Xia
- Fulian Qu
- Tian Yuan
- Yizhuo Zhang
View Affiliations

Affiliations: Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China
Published online on: October 13, 2015 https://doi.org/10.3892/ol.2015.3802
Pages: 3339-3344

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It is becoming increasingly evident that B‑cell receptor (BCR) signaling is central to the development and function of B cells. BCR signaling has emerged as a pivotal pathway and a key driver of numerous B‑cell lymphomas. Disruption of BCR signaling can be lethal to malignant B cells. Recently, kinase inhibitors that target BCR signaling have induced notable clinical responses. These inhibitors include spleen tyrosine kinase, mammalian target of rapamycin, phosphoinositide 3'‑kinase and Bruton's tyrosine kinase (BTK). Ibrutinib, an oral irreversible BTK inhibitor, has emerged as a promising targeted therapy for patients with B‑cell malignancies. The present review discusses the current understanding of BTK‑mediated BCR signaling in the biology and pathobiology of normal and malignant B cells, and the cellular interaction with the tumor microenvironment. The data on ibrutinib in the preclinical and clinical settings is also discussed, and perspectives for the future use of ibrutinib are outlined.

View Figures

View References

1	Younes A: Beyond chemotherapy: New agents for targeted treatment of lymphoma. Nat Rev Clin Oncol. 8:85–96. 2011. View Article : Google Scholar : PubMed/NCBI
2	Manzur S, Cohen S, Haimovich J and Hollander N: Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma. Clin Exp Immunol. 170:291–299. 2012. View Article : Google Scholar : PubMed/NCBI
3	Friedberg JW: New strategies in diffuse large B-cell lymphoma: Translating findings from gene expression analyses into clinical practice. Clin Cancer Res. 17:6112–6117. 2011. View Article : Google Scholar : PubMed/NCBI
4	Timmerman JM, Byrd JC, Andorsky DJ, et al: A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. Clin Cancer Res. 18:5752–5760. 2012. View Article : Google Scholar : PubMed/NCBI
5	Fowler N and Oki Y: Developing novel strategies to target B-cell malignancies. Am Soc Clin Oncol Educ Book. 366–372. 2013. View Article : Google Scholar : PubMed/NCBI
6	Ramsay AD and Rodriguez-Justo M: Chronic lymphocytic leukaemia-the role of the microenvironment pathogenesis and therapy. Br J Haematol. 162:15–24. 2013. View Article : Google Scholar : PubMed/NCBI
7	Gupta P, Goldenberg DM, Rossi EA and Chang CH: Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. Blood. 116:3258–3267. 2010. View Article : Google Scholar : PubMed/NCBI
8	Roschewski M, Dunleavy K and Wilson WH: Diffuse large B cell lymphoma: Molecular targeted therapy. Int J Hematol. 96:552–561. 2012. View Article : Google Scholar : PubMed/NCBI
9	Kenkre VP and Kahl BS: The future of B-cell lymphoma therapy: The B-cell receptor and its downstream pathways. Curr Hematol Malig Rep. 7:216–220. 2012. View Article : Google Scholar : PubMed/NCBI
10	Sison EA, Rau RE, McIntyre E, Li L, Small D and Brown P: MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism. Br J Haematol. 160:785–797. 2013. View Article : Google Scholar : PubMed/NCBI
11	Chen L, Monti S, Juszczynski P, et al: SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 23:826–838. 2013. View Article : Google Scholar : PubMed/NCBI
12	Irish JM, Myklebust JH, Alizadeh AA, et al: B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci USA. 107:12747–12754. 2010. View Article : Google Scholar : PubMed/NCBI
13	Young RM and Staudt LM: Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 12:229–243. 2013. View Article : Google Scholar : PubMed/NCBI
14	Shain KH and Tao J: The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies. Oncogene. 33:4107–4113. 2014. View Article : Google Scholar : PubMed/NCBI
15	Rickert RC: New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol. 13:578–591. 2013. View Article : Google Scholar : PubMed/NCBI
16	Choi MY and Kipps TJ: Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J. 18:404–410. 2012. View Article : Google Scholar : PubMed/NCBI
17	Stevenson FK, Krysov S, Davies AJ, et al: B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 118:4313–4320. 2011. View Article : Google Scholar : PubMed/NCBI
18	Chen L, Huynh L, Apgar J, et al: ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood. 111:2685–2692. 2008. View Article : Google Scholar : PubMed/NCBI
19	Depoil D, Fleire S, Treanor BL, et al: CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membrane-bound ligand. Nat Immunol. 9:63–72. 2008. View Article : Google Scholar : PubMed/NCBI
20	Niiro H and Clark EA: Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol. 2:945–956. 2002. View Article : Google Scholar : PubMed/NCBI
21	Humphries LA, Dangelmaier C, Sommer K, et al: Tec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase Cgamma Src homology 2-Src homology 3 linker. J Biol Chem. 279:37651–37661. 2004. View Article : Google Scholar : PubMed/NCBI
22	Hashimoto A, Okada H, Jiang A, et al: Involvement of guanosine triphosphatases and phospholipase C-gamma2 in extracellular signal-regulated kinase, c-Jun NH2-terminal kinase, and p38 mitogen-activated protein kinase activation by the B cell antigen receptor. J Exp Med. 188:1287–1295. 1998. View Article : Google Scholar : PubMed/NCBI
23	Shinohara M, Koga T, Okamoto K, et al: Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell. 132:794–806. 2008. View Article : Google Scholar : PubMed/NCBI
24	Davis RE, Ngo VN, Lenz G, et al: Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 463:88–92. 2010. View Article : Google Scholar : PubMed/NCBI
25	Khan WN: Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase. Immunol Res. 23:147–156. 2001. View Article : Google Scholar : PubMed/NCBI
26	Hamblin TJ, Davis Z, Gardiner A, Oscier DG and Stevenson FK: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 94:1848–1854. 1999.PubMed/NCBI
27	Gobessi S, Laurenti L, Longo PG, et al: ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood. 109:2032–2039. 2007. View Article : Google Scholar : PubMed/NCBI
28	Genevier HC, Hinshelwood S, Gaspar HB, et al: Expression of Bruton's tyrosine kinase protein within the B cell lineage. Eur J Immunol. 24:3100–3105. 1994. View Article : Google Scholar : PubMed/NCBI
29	Vargas L, Hamasy A, Nore BF and Smith CI: Inhibitors of BTK and ITK: State of the new drugs for cancer, autoimmunity and inflammatory diseases. Scand J Immunol. 78:130–139. 2013. View Article : Google Scholar : PubMed/NCBI
30	O'Hayre M, Salanga CL, Kipps TJ, et al: Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis. PLoS One. 5:e117162010. View Article : Google Scholar : PubMed/NCBI
31	Redondo-Muñoz J, Escobar-Díaz E, Samaniego R, et al: MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood. 108:3143–3151. 2006. View Article : Google Scholar : PubMed/NCBI
32	Richards KL, Motsinger-Reif AA, Chen HW, et al: Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. Cancer Res. 73:5029–5039. 2013. View Article : Google Scholar : PubMed/NCBI
33	Herman SE, Sun X, McAuley EM, et al: Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia. 27:2311–2321. 2013. View Article : Google Scholar : PubMed/NCBI
34	Chang BY, Huang MM, Francesco M, et al: The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 13:R1152011. View Article : Google Scholar : PubMed/NCBI
35	Lee KG, Xu S, Wong ET, Tergaonkar V and Lam KP: Bruton's tyrosine kinase separately regulates NFkappaB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B cells. J Biol Chem. 283:11189–11198. 2008. View Article : Google Scholar : PubMed/NCBI
36	Mráz M, Doubek M and Mayer J: Inhibition of B cell receptor signaling: A first targeted therapeutic approach for chronic lymphocytic leukemia and other B cell lymphomas. Klin Onkol. 26:179–185. 2013.(In Czech). View Article : Google Scholar : PubMed/NCBI
37	Tai YT, Chang BY, Kong SY, et al: Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 120:1877–1887. 2012. View Article : Google Scholar : PubMed/NCBI
38	Herman SE, Gordon AL, Hertlein E, et al: Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 117:6287–6296. 2011. View Article : Google Scholar : PubMed/NCBI
39	Schwamb J, Feldhaus V, Baumann M, et al: B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides. Blood. 120:3978–3985. 2012. View Article : Google Scholar : PubMed/NCBI
40	Yang Y, Shaffer AL III, Emre NC, et al: Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 21:723–737. 2012. View Article : Google Scholar : PubMed/NCBI
41	Dasmahapatra G, Patel H, Dent P, et al: The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol. 161:43–56. 2013. View Article : Google Scholar : PubMed/NCBI
42	Rushworth SA, Bowles KM, Barrera LN, et al: BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. Cell Signal. 25:106–112. 2013. View Article : Google Scholar : PubMed/NCBI
43	de Rooij MF, Kuil A, Geest CR, et al: The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 119:2590–2594. 2012. View Article : Google Scholar : PubMed/NCBI
44	Sabine P, Balasubramanian S, Pham LV, et al: Activity of Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in mantle cell lymphoma (MCL) identifies Btk as a novel therapeutic target. Blood (ASH Annual Meeting Abstracts). 118:36882011.
45	Honigberg LA, Smith AM, Sirisawad M, et al: The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 107:13075–13080. 2010. View Article : Google Scholar : PubMed/NCBI
46	O'Brien SMD, Furman RR, Coutre SE, et al: Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 15:48–58. 2014. View Article : Google Scholar : PubMed/NCBI
47	Advani RH, Buggy JJ, Sharman JP, et al: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 31:88–94. 2013. View Article : Google Scholar : PubMed/NCBI
48	Byrd JC, Furman RR, Coutre SE, et al: Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 369:32–42. 2013. View Article : Google Scholar : PubMed/NCBI
49	Wang L, Martin P, Blum KA, et al: The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): Preliminary results of a phase II trial. Blood (ASH Annual Meeting Abstracts). 118:4422011.
50	Staudt LM, Dunleavy K, Buggy JJ, et al: The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 modulates chronic active BCR signaling and induces tumor regression in relapsed/refractory ABC DLBCL. Blood (ASH Annual Meeting Abstracts). 118:31742011.
51	Wilson WH, Gerecitano JF, Goy A, et al: The Bruton's tyrosine kinase (BTK) inhibitor, Ibrutinib (PCI-32765), Has Preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): Interim results of a multicenter, open-label, phase 2 study. Blood (ASH Annual Meeting Abstracts). 120:6862012.
52	Fowler NH, Advani RH, Sharman JP, et al: The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma. Blood (ASH Annual Meeting Abstracts). 120:1562012.
53	Jaglowski SM, Jones JA, Flynn JM, et al: A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J Clin Oncol (2012 ASCO Annual Meeting). 30:65082012.
54	O'Brien S, Burger JA, Blum KA, et al: The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Follow-up of a phase Ib/II study. Blood (ASH Annual Meeting Abstracts). 120:9832011.
55	Burger JA, Keating MJ, Wierda WG, et al: Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: A single-arm, phase 2 study. Lancet. 15:1090–1099. 2014. View Article : Google Scholar : PubMed/NCBI
56	O'Brien SM, Barrientos JC, Flinn IW, et al: Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine(B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/IIstudy. J Clin Oncol (2012 ASCO Annual Meeting). 30:65152012.
57	Brown JRBJ, Flinn I, et al: The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib combined with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL, interim results of a phase Ib/II study. EHA Meeting Abstracts. 97:2012.